Ptc Therapeutics, Inc. Earnings

Ptc Therapeutics, Inc.’s revenue jumped 0.11% since last year same period to $196.79Mn in the Q3 2024. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 5.4% jump in its revenue since last 3-months.

Ptc Therapeutics, Inc.’s net profit jumped 19.79% since last year same period to $-106.65Mn in the Q3 2024. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -7.54% fall in its net profits since last 3-months.

Ptc Therapeutics, Inc.’s net profit margin jumped 19.88% since last year same period to -54.2% in the Q3 2024. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -2.03% fall in its net profit margins since last 3-months.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.44 - a -37.14% fall from last quarter’s estimates.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.44.

Ptc Therapeutics, Inc.’s earning per share (EPS) jumped 21.02% since last year same period to -1.39 in the Q3 2024. This indicates that the Ptc Therapeutics, Inc. has generated 21.02% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ptc Therapeutics, Inc.’s return on assets (ROA) stands at -0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ptc Therapeutics, Inc.’s return on equity (ROE) stands at -77.4.